Acute Coronary Syndrome – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Acute Coronary Syndrome – Pipeline Review, H2 2016’, provides an overview of the Acute Coronary Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Coronary Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Coronary Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Acute Coronary Syndrome

The report reviews pipeline therapeutics for Acute Coronary Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Acute Coronary Syndrome therapeutics and enlists all their major and minor projects

The report assesses Acute Coronary Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Acute Coronary Syndrome

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Acute Coronary Syndrome

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Acute Coronary Syndrome pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

advanceCor GmbH

Arena Pharmaceuticals, Inc.

Ascendia Pharmaceuticals LLC

Athera Biotechnologies AB

Bayer AG

Cardiome Pharma Corp.

Cerenis Therapeutics Holding SA

CSL Limited

Esperion Therapeutics, Inc.

HitGen LTD

Japan Tobacco Inc.

Lee's Pharmaceutical Holdings Limited

LipimetiX Development Inc

MedImmune LLC

Pfizer Inc.

The Medicines Company

Verseon Corporation

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Acute Coronary Syndrome Overview 8

Therapeutics Development 9

Pipeline Products for Acute Coronary Syndrome - Overview 9

Acute Coronary Syndrome - Therapeutics under Development by Companies 10

Acute Coronary Syndrome - Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Acute Coronary Syndrome - Products under Development by Companies 14

Acute Coronary Syndrome - Companies Involved in Therapeutics Development 15

advanceCor GmbH 15

Arena Pharmaceuticals, Inc. 16

Ascendia Pharmaceuticals LLC 17

Athera Biotechnologies AB 18

Bayer AG 19

Cardiome Pharma Corp. 20

Cerenis Therapeutics Holding SA 21

CSL Limited 22

Esperion Therapeutics, Inc. 23

HitGen LTD 24

Japan Tobacco Inc. 25

Lee's Pharmaceutical Holdings Limited 26

LipimetiX Development Inc 27

MedImmune LLC 28

Pfizer Inc. 29

The Medicines Company 30

Verseon Corporation 31

Acute Coronary Syndrome - Therapeutics Assessment 32

Assessment by Monotherapy Products 32

Assessment by Target 33

Assessment by Mechanism of Action 35

Assessment by Route of Administration 37

Assessment by Molecule Type 39

Drug Profiles 41

4-WF - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

AEM-28 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

AEM-2802 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Biologics for Acute Coronary Syndrome - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

CER-001 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

clopidogrel bisulphate - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

COR-2 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

CSL-112 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

dalcetrapib - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

MDCO-216 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

MEDI-6012 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

PC-mAb - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

PF-06282999 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

PMC-6 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

PR-15 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

rivaroxaban - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Small Molecules to Inhibit PCSK9 for Acute Coronary Syndrome and Atherosclerosis - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

temanogrel hydrochloride - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

tirofiban hydrochloride - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

ZK-001 - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Acute Coronary Syndrome - Dormant Projects 90

Acute Coronary Syndrome - Discontinued Products 92

Acute Coronary Syndrome - Product Development Milestones 94

Featured News & Press Releases 94

Sep 01, 2016: FDA Approves New AGGRASTAT Product Format 94

Aug 30, 2016: Completion of patient enrolment in the CARAT study - meeting the clinical schedule 94

Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial 95

Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics 96

Jul 07, 2016: Medicure Receives Response Letter from FDA on AGGRASTAT sNDA for New Indication 97

May 11, 2016: Medicure Files Application for New AGGRASTAT Product Format 98

Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial 98

Apr 25, 2016: Patent Term for Rivaroxaban Extended in US 99

Dec 14, 2015: The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published in European Heart Journal- Cardiovascular Pharmacotherapy 101

Nov 10, 2015: Cerenis Therapeutics: New Data for CER-001 Presented in Key Oral Session at American Heart Association Conference 2015 103

Sep 08, 2015: First patients enter phase II CARAT trial to assess reduction in atherosclerotic plaque using CER-001 in post Acute Coronary Syndrome (ACS) patients 103

Jul 23, 2015: Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides 104

Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery 105

May 11, 2015: Xarelto Bleeding Lawsuit Judge Orders the Selection of Cases for Discovery, Reports Xarelto Lawsuit Funding Firm, Fair Rate Funding 106

Appendix 108

Methodology 108

Coverage 108

Secondary Research 108

Primary Research 108

Expert Panel Validation 108

Contact Us 108

Disclaimer 109

List of Tables

List of Tables

Number of Products under Development for Acute Coronary Syndrome, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Acute Coronary Syndrome – Pipeline by advanceCor GmbH, H2 2016 15

Acute Coronary Syndrome – Pipeline by Arena Pharmaceuticals, Inc., H2 2016 16

Acute Coronary Syndrome – Pipeline by Ascendia Pharmaceuticals LLC, H2 2016 17

Acute Coronary Syndrome – Pipeline by Athera Biotechnologies AB, H2 2016 18

Acute Coronary Syndrome – Pipeline by Bayer AG, H2 2016 19

Acute Coronary Syndrome – Pipeline by Cardiome Pharma Corp., H2 2016 20

Acute Coronary Syndrome – Pipeline by Cerenis Therapeutics Holding SA, H2 2016 21

Acute Coronary Syndrome – Pipeline by CSL Limited, H2 2016 22

Acute Coronary Syndrome – Pipeline by Esperion Therapeutics, Inc., H2 2016 23

Acute Coronary Syndrome – Pipeline by HitGen LTD, H2 2016 24

Acute Coronary Syndrome – Pipeline by Japan Tobacco Inc., H2 2016 25

Acute Coronary Syndrome – Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 26

Acute Coronary Syndrome – Pipeline by LipimetiX Development Inc, H2 2016 27

Acute Coronary Syndrome – Pipeline by MedImmune LLC, H2 2016 28

Acute Coronary Syndrome – Pipeline by Pfizer Inc., H2 2016 29

Acute Coronary Syndrome – Pipeline by The Medicines Company, H2 2016 30

Acute Coronary Syndrome – Pipeline by Verseon Corporation, H2 2016 31

Assessment by Monotherapy Products, H2 2016 32

Number of Products by Stage and Target, H2 2016 34

Number of Products by Stage and Mechanism of Action, H2 2016 36

Number of Products by Stage and Route of Administration, H2 2016 38

Number of Products by Stage and Molecule Type, H2 2016 40

Acute Coronary Syndrome – Dormant Projects, H2 2016 90

Acute Coronary Syndrome – Dormant Projects (Contd..1), H2 2016 91

Acute Coronary Syndrome – Discontinued Products, H2 2016 92

Acute Coronary Syndrome – Discontinued Products (Contd..1), H2 2016 93

List of Figures

List of Figures

Number of Products under Development for Acute Coronary Syndrome, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 32

Number of Products by Top 10 Targets, H2 2016 33

Number of Products by Stage and Top 10 Targets, H2 2016 33

Number of Products by Top 10 Mechanism of Actions, H2 2016 35

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 35

Number of Products by Routes of Administration, H2 2016 37

Number of Products by Stage and Routes of Administration, H2 2016 37

Number of Products by Molecule Types, H2 2016 39

Number of Products by Stage and Molecule Types, H2 2016 39

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports